Rosar, F.; Kochems, N.; Bartholomä, M.; Maus, S.; Stemler, T.; Linxweiler, J.; Khreish, F.; Ezziddin, S.
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers 2021, 13, 3095.
https://doi.org/10.3390/cancers13123095
AMA Style
Rosar F, Kochems N, Bartholomä M, Maus S, Stemler T, Linxweiler J, Khreish F, Ezziddin S.
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers. 2021; 13(12):3095.
https://doi.org/10.3390/cancers13123095
Chicago/Turabian Style
Rosar, Florian, Niklas Kochems, Mark Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Fadi Khreish, and Samer Ezziddin.
2021. "Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function" Cancers 13, no. 12: 3095.
https://doi.org/10.3390/cancers13123095
APA Style
Rosar, F., Kochems, N., Bartholomä, M., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., & Ezziddin, S.
(2021). Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers, 13(12), 3095.
https://doi.org/10.3390/cancers13123095